Drug intelligence / Profile preview

aminophylline + diphenhydramine

Development stage
Unknown
Lead developer
Scotmann Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Scot's Expectorant is a combination pharmaceutical product developed by Scotmann Pharmaceuticals for the treatment of respiratory and allergic conditions. It contains aminophylline, a bronchodilator that works by relaxing bronchial smooth muscle through phosphodiesterase inhibition and adenosine receptor antagonism, and diphenhydramine, a first-generation antihistamine that acts as a competitive antagonist at the H1 receptor. This combination is typically used to alleviate symptoms associated with asthma, bronchitis, and allergic rhinitis where both bronchospasm and allergic inflammation are present. It is currently approved for use.

Brand names
Scot's Expectorant
Other names
Aminophyllin + Diphenhydramine
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)PDE3/4 (Cyclic nucleotide phosphodiesterase 3 and 4)ADOR (Adenosine receptors)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on aminophylline + diphenhydramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aminophylline + diphenhydramine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call